Clinical-stage biotechnology firm Imunon Inc. (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients.
The company reported site activation and patient enrollment speeds that significantly outpace original forecasts and standard industry benchmarks.
Enrollment Rates Exceed Industry Benchmarks
The trial progressed from protocol submission to site activation in roughly six months. It reached its first randomized patient within two months of approval—one-third of the standard industry benchmark.
Current study-level enrollment stands at approximately 0.5 patients per site each month, beating the company’s initial target of 0.3 and historical industry averages of roughly 0.2. Over 70% of active sites are currently matching or surpassing the projected monthly targets.
Clinical Timeline And Interim Regulatory Goals
Imunon now projects full enrollment completion by the second quarter of 2029.
High conversion rates from pre-screening to randomization, backed by promising overall survival data from the Phase 2 OVATION 2 study, have fueled participant interest.
Furthermore, two pre-planned interim analyses are scheduled to potentially enable an early Biologics License Application submission for full regulatory approval if specific targets are reached.
Strong Safety Profile Confirmed
IMNN-001 has maintained a favorable safety and tolerability profile throughout the trial.
Researchers observed no instances of cytokine release syndrome, systemic toxicities, or serious immune-related adverse events. Safety outcomes remain comparable between the treatment arm (IMNN-001 with neoadjuvant and adjuvant chemotherapy) and the control arm, consistent with findings from an ongoing Phase 2 Minimal Residual Disease study.
Recent Independent Data Monitoring Committee reviews noted no safety concerns across ongoing studies.
IMNN Stock Price Activity: Imunon shares were up 1.95% at $1.57 during premarket trading Thursday, according to Benzinga Pro data.
Photo by Aunt Spray via Shutterstock
Recent Comments